Encoded Therapeutics Reports Strong ETX101 Results
SOUTH SAN FRANCISCO, Calif. – May 13, 2026 Encoded Therapeutics presented expanded clinical data from its ongoing POLARIS Phase...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Bispecific Antibody cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Neurodegenerative Disease Oncology oncology innovation Ophthalmology Orphan Drug orphan drug designation Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SOUTH SAN FRANCISCO, Calif. – May 13, 2026 Encoded Therapeutics presented expanded clinical data from its ongoing POLARIS Phase...
SOUTH SAN FRANCISCO, Calif., April 27, 2026 Encoded Therapeutics announced its participation in the 29th Annual Meeting of the...
